Clinical trials: Stage I Ovarian Cancer
Endometrial Carcinoma, Ovarian Cancer
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
The aim of this study is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of bemarituzimab given in combination with a fixed dose of bevacizumab and to assess the clinical activity of the proposed…
- Conditions
- Endometrial Carcinoma, Ovarian Cancer, Cervix Cancer
- Trial name
- ANGELICA (NCT07146919)
- Testing
- Bemarituzumab, Bevacizumab
- Sponsor
- Centre Leon Berard
Prostate Cancers, Breast Cancer
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.
- Conditions
- Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer
- Trial name
- ADVICE (NCT06926075)
- Testing
- A novel hGIIA-Vimentin Inhibitor, Dose expansion
- Where
- 3 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Filamon LTD
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody, paclitaxel, and interferon alfa in treating patients who have ovarian cancer.
- Trial name
- NCT00002734
- Testing
- recombinant interferon alfa, chemotherapy, paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed.
- Conditions
- Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor
- Trial name
- NCT03067181
- Testing
- Best Practice, Biopsy Procedure, Biospecimen Collection
- Where
- 629 sites in United States, Australia and 7 more
- Volunteers
- 1,780 people
- Sponsor
- Children's Oncology Group
Fallopian Tube Neoplasms, Peritoneal Neoplasms
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve [AUC]=6) in patients with…
- Conditions
- Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00407407
- Testing
- ABI-007, Carboplatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Celgene
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD)…
- Conditions
- Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
- Trial name
- NCT04196257
- Testing
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bio-Path Holdings, Inc.
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03552471
- Testing
- Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer that has spread to…
- Conditions
- Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Trial name
- NCT01749397
- Testing
- Floxuridine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00287859
- Testing
- topotecan hydrochloride
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Fallopian Tube Cancer
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
- Trial name
- NCT01220154
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- David O'Malley
Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
- Trial name
- NCT00335998
- Testing
- triapine, laboratory biomarker analysis, external beam radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ovarian Carcinoma
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in treating patients with advanced solid tumors.
- Conditions
- Advanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma
- Trial name
- NCT03756818
- Testing
- Mivavotinib, Paclitaxel, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005051
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 10 sites in United States
- Sponsor
- NYU Langone Health
Ovarian Cancer, Peritoneal Cancer
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
The best way to treat MBO in patients with ovarian cancer has not been studied enough by trials that assess how more than one treatment arm (surgical, chemotherapeutic, supportive care approaches) affects clinical outcomes like…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Bowel Obstruction
- Trial name
- NCT01083537
- Testing
- Cisplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of veliparib when given together with carboplatin, paclitaxel, and bevacizumab in treating patients with newly diagnosed stage II-IV ovarian epithelial, fallopian tube, or…
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT00989651
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 23 sites in United States
- Volunteers
- 431 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Vaccines made from monoclonal antibodies combined with tumor cells may make the body build an immune response to kill tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00058435
- Testing
- abagovomab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC, Low Grade Serous Ovarian Cancer
Phase I Trial of Defactinib and VS-6766.
This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, VS-6766 (RO5126766) in patients with advanced solid…
- Conditions
- NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
- Trial name
- FRAME (NCT03875820)
- Testing
- VS-6766, Defactinib
- Where
- 5 sites in United Kingdom
- Volunteers
- 87 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Ovarian Cancer
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6…
- Trial name
- NCT00526799
- Testing
- Sorafenib, Topotecan
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daniela Matei, MD